Alita Miller, Ph.D.

Alita is an expert in antibacterial discovery and development with over 20 years of experience in the field.  Prior to joining ArrePath, she was Senior Vice President of Biology at Entasis Therapeutics, a company dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria.  At Entasis, Alita oversaw both preclinical biology and developmental microbiology research and played a key role in the development of Xacduro, which was FDA-approved in 2023.  Prior to Entasis, Alita was first at Pfizer where she led both large and small molecule antibacterial discovery projects and then at AstraZeneca, where she was Head of Microbial Genetics and Genomics.  She has served on numerous NIAID review panels and Scientific Advisory Boards related to the field.

Alita obtained a BA in chemistry from Kalamazoo College and worked as a chemist at both Merck and Eli Lilly before obtaining a PhD in Biochemistry and Molecular Biology from the University of Chicago.  Her postdoctoral training was in the DiRita lab at the University of Michigan characterizing the molecular drivers of pathogenesis in Streptococcus pyogenes.